BioCentury | Feb 28, 2017
Distillery Therapeutics

Renal

...PKD. Regulus Therapeutics Inc. has the anti-miR-17 compound RGLS4326 in preclinical testing to treat PKD. Microlin Bio Inc....
BioCentury | Apr 28, 2016
Finance

Public-Private Partnership Roundup

...proof of concept in animal models," said Hegendörfer. Micro move into AD MicroRNA (miRNA) company Microlin Bio Inc....
...Inc. (KOSDAQ:038290), Seoul, South Korea Max Planck Society, Munich, Germany MedGenome Inc., San Francisco, Calif. Microlin Bio Inc....
BioCentury | Apr 11, 2016
Company News

Marina Biotech, Microlin Bio deal

...completion of a financing of at least $5 million. Marina Biotech Inc. (Pink:MRNA), Bothell, Wash. Microlin Bio Inc....
BioCentury | Feb 15, 2016
Company News

Universite Laval, Microlin Bio deal

...details, and the university did not respond to inquiries. Universite Laval , Quebec City, Quebec Microlin Bio Inc....
BioCentury | Jan 4, 2016
Company News

Microlin Bio, American Boarding deal

...Microlin Bio reverse-merged with American Boarding. Microlin Bio is developing microRNA-based therapies for cancer. Its lead candidate...
...AM-21 ), an anti- microRNA-21 (miR-21) , is in preclinical testing to treat lung cancer. Microlin Bio Inc....
BioCentury | Oct 12, 2015
Clinical News

Microlin Bio preclinical data

...No signs of treatment-based toxicity were reported. The product is an anti- microRNA-21 (miR-21) . Microlin Bio Inc....
BioCentury | Sep 22, 2014
Financial News

Microlin Bio withdraws IPO

Microlin Bio Inc. , New York, N.Y. Business: Cancer Date announced: 2014-09-19 Type: IPO Underwriters: Brean Capital; Summer Street; Meyers Associates Note: The company withdrew its IPO on NASDAQ, citing market conditions. WIR Staff...
BioCentury | Sep 20, 2014
Financial News

Microlin pulls IPO

Microlin Bio Inc. (New York, N.Y.) withdrew its IPO on NASDAQ, citing market conditions. In June the company amended its IPO to sell 5.5 million units consisting of one share and one warrant at $4.50-$5.50....
BioCentury | Aug 11, 2014
Finance

Choppy IPO waters

...to advance the compound for the indication only with a partner or with non-dilutive financing. Microlin Bio Inc....
...Switzerland Avalanche Biotechnologies Inc. (NASDAQ:AAVL), Menlo Park, Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Microlin Bio Inc....
BioCentury | Aug 8, 2014
Financial News

Tobira postpones IPO

...and CCR2 antagonist to treat non-alcoholic steatohepatitis (NASH) this half. Earlier this week, microRNA company Microlin Bio Inc....
Items per page:
1 - 10 of 21
BioCentury | Feb 28, 2017
Distillery Therapeutics

Renal

...PKD. Regulus Therapeutics Inc. has the anti-miR-17 compound RGLS4326 in preclinical testing to treat PKD. Microlin Bio Inc....
BioCentury | Apr 28, 2016
Finance

Public-Private Partnership Roundup

...proof of concept in animal models," said Hegendörfer. Micro move into AD MicroRNA (miRNA) company Microlin Bio Inc....
...Inc. (KOSDAQ:038290), Seoul, South Korea Max Planck Society, Munich, Germany MedGenome Inc., San Francisco, Calif. Microlin Bio Inc....
BioCentury | Apr 11, 2016
Company News

Marina Biotech, Microlin Bio deal

...completion of a financing of at least $5 million. Marina Biotech Inc. (Pink:MRNA), Bothell, Wash. Microlin Bio Inc....
BioCentury | Feb 15, 2016
Company News

Universite Laval, Microlin Bio deal

...details, and the university did not respond to inquiries. Universite Laval , Quebec City, Quebec Microlin Bio Inc....
BioCentury | Jan 4, 2016
Company News

Microlin Bio, American Boarding deal

...Microlin Bio reverse-merged with American Boarding. Microlin Bio is developing microRNA-based therapies for cancer. Its lead candidate...
...AM-21 ), an anti- microRNA-21 (miR-21) , is in preclinical testing to treat lung cancer. Microlin Bio Inc....
BioCentury | Oct 12, 2015
Clinical News

Microlin Bio preclinical data

...No signs of treatment-based toxicity were reported. The product is an anti- microRNA-21 (miR-21) . Microlin Bio Inc....
BioCentury | Sep 22, 2014
Financial News

Microlin Bio withdraws IPO

Microlin Bio Inc. , New York, N.Y. Business: Cancer Date announced: 2014-09-19 Type: IPO Underwriters: Brean Capital; Summer Street; Meyers Associates Note: The company withdrew its IPO on NASDAQ, citing market conditions. WIR Staff...
BioCentury | Sep 20, 2014
Financial News

Microlin pulls IPO

Microlin Bio Inc. (New York, N.Y.) withdrew its IPO on NASDAQ, citing market conditions. In June the company amended its IPO to sell 5.5 million units consisting of one share and one warrant at $4.50-$5.50....
BioCentury | Aug 11, 2014
Finance

Choppy IPO waters

...to advance the compound for the indication only with a partner or with non-dilutive financing. Microlin Bio Inc....
...Switzerland Avalanche Biotechnologies Inc. (NASDAQ:AAVL), Menlo Park, Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Microlin Bio Inc....
BioCentury | Aug 8, 2014
Financial News

Tobira postpones IPO

...and CCR2 antagonist to treat non-alcoholic steatohepatitis (NASH) this half. Earlier this week, microRNA company Microlin Bio Inc....
Items per page:
1 - 10 of 21